Ultragenyx Pharmaceutical | RARE - Trade Debtors


Ultragenyx Pharmaceutical reported $60M in Trade Debtors for its fiscal quarter ending in March of 2026.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 148.38M 153K Mar/2026
Agios Pharmaceuticals USD 16.13M 5.56M Mar/2026
Alnylam Pharmaceuticals USD 883.96M 106.39M Mar/2026
BioCryst Pharmaceuticals USD 106.82M 15.49M Dec/2025
BioMarin Pharmaceutical USD 903.91M 4.3M Mar/2026
Esperion Therapeutics USD 140.19M 21.21M Dec/2025
Immunic USD 333K 156K Dec/2025
Insmed USD 178.55M 37.7M Mar/2026
Ionis Pharmaceuticals USD 74M 8M Mar/2026
Karyopharm Therapeutics USD 26.18M 5.6M Dec/2025
Kyowa Hakko Kirin JPY 120.9B 60.31B Mar/2026
MacroGenics USD 13.37M 55.86M Dec/2025
Moderna USD 71M 113M Mar/2026
Neurocrine Biosciences USD 768.1M 81.3M Mar/2026
PTC Therapeutics USD 181.62M 21.45M Dec/2025
Puma Biotechnology USD 28.1M 3.52M Jun/2024
Regeneron Pharmaceuticals USD 5.73B 10.1M Mar/2026
Sarepta Therapeutics USD 547.91M 149.68M Mar/2026
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
Vertex Pharmaceuticals USD 2B 56.7M Mar/2026
Xoma USD 14.78M 4.96M Jun/2024